UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
August 2017
Commission File Number: 001-38067
Verona Pharma plc
(Exact Name of Registrant as Specified in Its Charter)
3 More London Riverside
London SE1 2RE UK
+44 203 283 4200
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): o
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On August 21, 2017, Verona Pharma plc issued a release notification system announcement in the United Kingdom (the “RNS”) disclosing an acquisition by a person discharging managerial responsibilities.
The RNS is furnished herewith as Exhibit 99.1 to this Report on Form 6-K.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
|
VERONA PHARMA PLC | ||
|
|
|
| |
|
|
|
| |
|
Date: August 24, 2017 |
By: |
/s/ Jan-Anders Karlsson | |
|
|
|
Name: |
Jan-Anders Karlsson, Ph.D. |
|
|
|
Title: |
Chief Executive Officer |
EXHIBIT INDEX
|
Exhibit |
|
Description |
|
|
|
|
|
99.1 |
|
Release Notification System Announcement of Verona Pharma plc, dated August 21, 2017 |
Exhibit 99.1
PDMR Dealing
August 21, 2017, LONDON — Verona Pharma plc (AIM: VRP) (NASDAQ: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on August 17, 2017, Dr. David Ebsworth, Non-Executive Chairman of the Company, purchased 8,130 ordinary shares of 5 pence each in the Company (the “Ordinary Shares”) at a price of 122.5 pence per Ordinary Share. Following the acquisition, Dr. Ebsworth will have an interest in the Company of 125,787 Ordinary Shares, representing 0.12% of the Company’s issued share capital.
The notification of dealing form can be found below.
For further information, please contact:
|
Verona Pharma plc |
|
Tel: +44 (0)20 3283 4200 |
|
Jan-Anders Karlsson, Chief Executive Officer |
|
info@veronapharma.com |
|
|
|
|
|
N+1 Singer (Nominated Adviser and UK Broker) |
|
Tel: +44 (0)20 7496 3000 |
|
Aubrey Powell / James White |
|
|
|
|
|
|
|
FTI Consulting (UK Media and Investor enquiries) |
|
Tel: +44 (0)20 3727 1000 |
|
Simon Conway / Natalie Garland-Collins |
|
veronapharma@fticonsulting.com |
|
|
|
|
|
ICR, Inc. (US Media and Investor enquiries) |
|
|
|
Darcie Robinson |
|
Tel: +1 203-682-8379 |
|
Stephanie Carrington |
|
Tel. +1 646-277-1282 |
|
1 |
|
Details of the person discharging managerial responsibilities/person closely associated | ||
|
|
|
| ||
|
a) |
|
Name |
|
David Ebsworth |
|
|
|
|
|
|
|
2 |
|
Reason for the notification | ||
|
|
|
| ||
|
a) |
|
Position/status |
|
Non-Executive Chairman |
|
|
|
|
|
|
|
b) |
|
Initial notification/Amendment |
|
Initial notification |
|
3 |
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
|
|
|
| ||||
|
a) |
|
Name |
|
Verona Pharma plc | ||
|
|
|
|
|
| ||
|
b) |
|
LEI |
|
213800EVI6O6J3TIAL06 | ||
|
|
|
|
|
| ||
|
4 |
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||
|
|
|
| ||||
|
a) |
|
Description of the financial instrument, type of instrument Identification code |
|
Ordinary Shares of 5 pence each
| ||
|
|
|
|
|
| ||
|
b) |
|
Nature of the transaction |
|
David Ebsworth purchased 8,130 Ordinary Shares | ||
|
|
|
|
|
| ||
|
c) |
|
Price(s) and volume(s) |
|
Price(s) |
|
Volume(s) |
|
|
|
|
|
122.5 pence per Ordinary Share |
|
8,130 Ordinary Shares |
|
|
|
|
|
|
|
|
|
d) |
|
Aggregated information |
|
N/A | ||
|
|
|
|
|
| ||
|
|
|
· Aggregated volume |
|
| ||
|
|
|
|
|
| ||
|
|
|
· Price |
|
| ||
|
|
|
|
|
| ||
|
e) |
|
Date of the transaction |
|
17 August 2017 | ||
|
|
|
|
|
| ||
|
f) |
|
Place of the transaction |
|
London Stock Exchange, AIM | ||